O
3-induced airway inflammation is characterized by early neutrophilic infiltration followed by a mononuclear cell dominated inflammation (
Chitano et al. 1995). Molecular changes during the pulmonary pathogenesis induced by O
3 include increased production of prostaglandins, proinflammatory cytokines, and chemokines such as IL-6, IL-8, granulocyte macrophage colony-stimulating factor, KC, and MIP-2 (
Devlin et al. 1991;
Johnston et al. 2005a). In humans, neutrophil influx begins in peripheral airways as early as 6 hr after O
3 exposure and is known to be mediated by neutrophilic chemokines such as IL-8 and GRO-α (
Krishna et al. 1998). Functional roles of several inflammatory mediators such as tumor necrosis factor-α (TNF-α) (Cho et al. 2001;
Kleeberger et al. 1997), IL-6 (
Johnston et al. 2005b), and IL-1β (
Arsalane et al. 1995), and the transcription factors nuclear factor kappa B (
Cho et al. 2007;
Laskin et al. 2002) and activator protein (AP)-1 (
Cho et al. 2007) have also been determined in pulmonary inflammation of laboratory rodents exposed to O
3.
The primary functions of MMPs include degradation and turnover of ECM, tissue repair and remodeling, and leukocyte migration from peripheral circulation to inflammatory sites. Furthermore, recent findings suggested that MMPs can modulate inflammation and innate immunity by affecting the activity of various nonmatrix proteins (
Parks et al. 2004). MMP-9 has been thought to be particularly important in the pathogenesis of inflammatory lung diseases, including acute lung injury, asthma, and COPD (
Atkinson and Senior 2003). Higher than normal MMP-9 levels in the patients with these disorders may promote destruction of normal tissue architecture and increased migration of inflammatory cells to the disease sites (
Lemjabbar et al. 1999a,
1999b).
In the present study, we hypothesized that MMP-9 is essential for O
3-induced airway inflammation because MMP-9 is one of the most predominant MMPs found in inflammatory airway diseases (
Atkinson and Senior 2003). Contrary to predictions, we found that O
3-induced neutrophilic airway inflammation and injury were markedly increased in
Mmp9−/− mice compared with
Mmp9+/+ mice, indicating a protective role of MMP-9 in O
3-exposed airways. The results from the current study suggest that MMP-9 may not act primarily on ECM degradation that facilitates leukocyte migration to pulmonary inflammatory sites as indicated by another investigation (
Betsuyaku et al. 1999). Heightened neutrophilic inflammation was also associated with enhanced levels of KC and MIP-2, which are important chemokines for neutrophil recruitment to the lung.
MMP-9 has diverse effects on neutrophilic inflammation in experimental animal models. It enhances neutrophil chemotaxis in response to certain chemokines (
D’Haese et al. 2000) and increases neutrophil influx in glomerulonephritis (
Sternlicht and Werb 2001). Conversely, MMP-9 also has inhibitory effects on BALF neutrophilia (
Lanone et al. 2002); increased tissue neutrophil and inflammatory cell infiltration have been shown in
Mmp9−/−mice in response to epithelial injury and chemokine administration (
D’Haese et al. 2000;
Mohan R et al. 2002). Several lines of molecular evidence have determined that proteolytic function of MMP-9 affects cytokine and chemokine levels as well as their activities. For example, MMP-9 processes and activates pro-IL-1β (
Schonbeck et al. 1998), inactive membrane bound forms of TNF-α (
Mohan MJ et al. 2002), and transforming growth factor-β (TGF-β) (
Yu and Stamenkovic 2000). MMP-9 also processes CXC chemokines, which exert potent chemoattractant activities on leukocytes and alters their specific activities, but not CC chemokines (e.g., RANTES and MCP-2) (
Van den Steen et al. 2000). MMP-9 truncates IL-8 (1–77) into IL-8 (7–77), which enhances neutrophil activation more than 10-fold (
Van den Steen et al. 2000). In contrast, neutrophilic chemoattractant activity was decreased by MMP-9 degradation of the other CXC chemokines GRO-α and connective tissue–activating peptide (CTAP)-III (
Van den Steen et al. 2000). Our current observation that O
3 induced higher levels of BAL CXC chemokines KC and MIP-2 in
Mmp9−/− mice than in
Mmp9+/+ mice is consistent with, but does not prove, the notion that these chemokines were key effectors of pulmonary MMP-9. Interestingly, we also found no differences in the steady state mRNA levels of the O
3-increased KC and MIP-2 between
Mmp9+/+ and
Mmp9−/− mice. Together these results suggest that differences in these chemokine levels in
Mmp9−/− mice compared with those in
Mmp9+/+ mice were caused by translational or posttranslational processes, which may include degradation/cleavage by MMP-9.
Significantly greater elevation of MMP-2 level and activity were observed in
Mmp9−/− mice compared with
Mmp9+/+ mice after O
3 exposure. We cannot rule out the possibility that increased MMP-2 is a compensatory response in
Mmp9−/− mice and may be involved in increased neutrophilic airway inflammation. However, MMP-9 has been reported to be the dominant airway MMP controlling inflammatory cell egression (
Corry et al. 2004), and there is no evidence that MMP-2 has a modulating effect on inflammatory chemokines such as KC and MIP-2 (
Parks et al. 2004). In addition, neutrophil concentrations in BALF were not changed in
Mmp2−/− mice in a model of allergic asthma (
Corry et al. 2002). We therefore postulate that MMP-2 does not have a critical role in heightened neutrophilic inflammation in
Mmp9−/− mice, although it may be involved with other mechanisms of lung injury induced by O
3 exposure (e.g., lung hyperpermeability).
The role of MMP-7 in acute lung injury has been studied in mouse models of interstitial pulmonary diseases such as fibrosis:
Mmp7−/− mice had suppressed pulmonary fibrosis caused by bleomycin (
Li et al. 2002;
Zuo et al. 2002), and it was accompanied by decreased neutrophilic inflammation and chemokines (e.g., KC) in the alveolar fluid (
Li et al. 2002). We predicted that O
3-induced airway inflammation would be attenuated in
Mmp7−/− mice. However, the current findings suggest that MMP-7 is not significantly associated with O
3-induced airway inflammation and injury in mice. In addition, KC concentrations in BALF were not significantly different between
Mmp7−/− and
Mmp7+/+ mice in the current model (data not shown). No studies have investigated the role of MMP-7 in oxidative lung injury such as O
3. Different from MMP-9, matrilysin is produced by alveolar epithelial cells in injured lungs, and it has been thought to contribute to alveolar epithelial injury and re-epithelialization. Inhaled O
3 mostly affects centriacinar legions of the airway, but not alveoli, which may partially explain why MMP-7 deficiency failed to alter airway inflammation by O
3.
In summary, our results showed that deficiency in MMP-9 was associated with enhanced airway epithelial injury, neutrophil recruitment, and permeability following O3 exposure, but a deficiency in MMP-7 did not significantly affect O3-induced airway injury. The aberrant neutrophil recruitment was correlated with increased levels of KC and MIP-2 protein, but not mRNA expression, in the Mmp9−/− mice relative to Mmp9+/+ mice. Results are consistent with the hypothesis that enhanced O3-induced injury in Mmp−/− mice is related to a difference in posttranscriptional processing of these CXC chemokines in the airway. These findings increase our understanding of the pathophysiological process of O3-induced lung injury and suggest that MMP-9 produced in the lung in response to oxidative stimuli may have a beneficial function.